Diversifying Friedreich's Ataxia Portfolio

Lexeo Therapeutics (LXEO), a Nasdaq-listed gene therapy developer, has announced the acquisition of Mantle Therapeutics. The total transaction value reaches up to $21.3 million, comprising an upfront payment of $8.3 million ($5.3 million in cash and $3 million in common stock) plus potential clinical and regulatory milestones of up to $13 million. Friedreich's Ataxia (FA) is a rare genetic disorder that causes neurodegeneration and fatal cardiomyopathy due to frataxin (FXN) protein deficiency, and Lexeo has significantly bolstered its pipeline by diversifying single-asset risk through this acquisition.

Securing Clinical-Stage Oral Combination Drug LX3010 and Three Preclinical Assets

The core asset integrated through this deal is the clinical-stage oral combination therapy LX3010 (formerly MTL-104). In early clinical data from 11 patients, it demonstrated encouraging efficacy with a 6-point improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) compared to baseline. Additionally, Lexeo secured three preclinical pipeline assets (LX3030, LX3050, LX3070) targeting the frataxin protein to regulate mitochondrial iron balance and energy production. Based on its secured cash liquidity through 2028, Lexeo plans to prioritize programs and submit Investigational New Drug (IND) applications for next-generation candidates by 2027.

Securing Three Strategic Partnerships to Innovate CNS Drug Delivery

Alongside the asset acquisition, Lexeo simultaneously established three strategic partnerships to support sequential administration of gene therapies to the central nervous system (CNS). Weill Cornell Medicine has agreed to jointly research direct intracisternal administration routes. It secured an exclusive license option for the IgG-degrading enzyme (VTX-PID) to overcome AAV neutralizing antibodies from Vivet Therapeutics, and a license option for novel capsids capable of crossing the blood-brain barrier (BBB) from Apertura Gene Therapy, establishing a technical foundation to significantly improve AAV re-dosing and brain delivery efficiency.

Synergy from Accelerating the Pivotal Trial of Lead Pipeline LX2006

Despite the addition of new assets, Lexeo's top priority remains LX2006 (Phase 2/3), an AAVrh.10-based cardiomyopathy gene therapy. LX2006, which has received Breakthrough Therapy and Orphan Drug designations from the US FDA, is currently undergoing a pivotal trial, with topline data expected in the second half of 2027. The combination of the cardiac-targeted LX2006 with Mantle’s nervous system-targeted oral therapy and novel CNS delivery platforms marks a turning point for establishing exclusive leadership in the systemic disease area of FA.